We and others have shown that GLP-1 drugs reduce risks of many substance use and addiction disorders
Regarding newer agents, evidence from phase 2 trials indicates that the triple agonist retatrutide (GLP-1R/GIPR/GCGR) can achieve unprecedented weight loss of up to 24.4% (Jastreboff et al., 2023)
Cluster 1 included allergies, anxiety, depression, chronic obstructive pulmonary disease, fatigue, fever, hypertension, indigestion, insomnia, gastroesophageal reflux disease, hives, swelling, restlessness, and seizures
A structured approach can simplify this decision-making process: Assess cardiovascular and renal status : Patients with heart failure or kidney disease often benefit from SGLT2 inhibitors first
This system is activated by food, but also by drugs, alcohol, and other addictive behaviors
Besides, it improved the lipid profile and reduced blood pressure, i.e., much-improved cardiometabolic outcomes, and even its safety profile was comparable to other GLP-1, GIP, and glucagon receptor agonist classes, with reports of only transient gastrointestinal adverse events that were mild or moderate
